Peptide reference
KPV
Lysine-Proline-Valine ·Lys-Pro-Val ·α-MSH(11-13) ·alpha-MSH C-terminal tripeptide
What cited sources report about KPV
KPV is a synthetic tripeptide corresponding to the C-terminal three residues (Lys-Pro-Val) of α-melanocyte-stimulating hormone (α-MSH). The peptide is currently under review by the FDA Pharmacy Compounding Advisory Committee (PCAC), with a public meeting scheduled for July 23, 2026. As of the cited literature, KPV has no FDA-approved indication and no marketing authorization in any major jurisdiction. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
Lee et al. (2026) — Cytotechnology
A 2026 in-vitro investigation conducted at Pukyong National University in Busan, South Korea, examined KPV at 100 µg/mL in HepG2 hepatic epithelial cells exposed to oleic acid. The authors reported that KPV reduced intracellular reactive oxygen species generation, downregulated fatty acid synthase expression, and attenuated lipid accumulation in the model system. They characterized the peptide as an endogenous α-MSH-derived tripeptide and described the observed effects as preliminary mechanistic findings rather than a clinical claim.
This study examined the protective role of Lysine-Proline-Valine (KPV), an endogenous tripeptide derived from α-melanocyte-stimulating hormone, against oleic acid (OA)-induced oxidative damage and lipid accumulation in hepatic epithelial HepG2 cells.
Xiao et al. (2017) — Molecular Therapy
Researchers at Georgia State University’s Institute for Biomedical Sciences and Southwest University in Chongqing loaded KPV into hyaluronic-acid-functionalized polymeric nanoparticles (HA-KPV-NPs) and characterized the resulting particle size (~272 nm) and zeta potential. In a murine ulcerative-colitis model, the authors observed downregulation of TNF-α and accelerated mucosal healing in animals receiving the oral hydrogel-encapsulated nanoparticle formulation, compared with control formulations. The authors described KPV as a naturally occurring tripeptide and framed the work as a delivery-system study rather than a stand-alone efficacy claim for free KPV.
Lysine-proline-valine (KPV), a naturally occurring tripeptide, has been shown to attenuate the inflammatory responses of colonic cells.
PubChem — Lysylprolylvaline
The PubChem compound record for KPV catalogues the tripeptide Lys-Pro-Val, listing molecular formula and the synonym set that connects KPV to α-MSH(11-13). The record aggregates published chemical and pharmacological data and links to the supporting literature.
Coverage notes
Published KPV literature is dominated by in-vitro and rodent preclinical work, with no completed registered Phase II/III clinical trials in humans indexed on ClinicalTrials.gov as of the last_updated date. No FDA-approved indication exists. This page will be updated when the July 2026 PCAC briefing materials are released.